Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY:
Cryptosporidiosis remains a significant public health threat. Risk avoidance guidance could be viewed in the more relative terms of risk management depending on the degree of immunosuppression. Of established efficacy in immunocompetent patients, nitazoxanide is also useful for immunocompromised patients. Better prevention and treatment options mean that, in the immunocompromised, this disease is now less common. Immune reconstitution is the key to prevention. Further database mining of the Cryptosporidium genome will assist in the discovery of new genes, biochemical pathways and protective antigens that can be targeted to develop novel therapies for cryptosporidiosis.
|
Authors | Huw V Smith, Gerard D Corcoran |
Journal | Current opinion in infectious diseases
(Curr Opin Infect Dis)
Vol. 17
Issue 6
Pg. 557-64
(Dec 2004)
ISSN: 0951-7375 [Print] United States |
PMID | 15640710
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- AIDS-Related Opportunistic Infections
(drug therapy)
- Animals
- Antiprotozoal Agents
(therapeutic use)
- Cryptosporidiosis
(drug therapy)
- Cryptosporidium
(drug effects, isolation & purification)
- Humans
|